Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

John A. Eckman, Patricia M. Sterba, Denise Kelly, Val Alexander, Mark Chang Hwa Liu, Bruce S. Bochner, Donald Macglashan, Sarbjit S Saini

Research output: Contribution to journalArticle

Abstract

Background: Omalizumab treatment suppresses Fcε{lunate}RI expression faster on blood basophils than skin mast cells. Objective: We used omalizumab to elucidate the relative contributions of basophil versus mast cell Fcε{lunate}RI activation in a nasal allergen challenge (NAC) model. Methods: Eighteen subjects with cat allergy were enrolled in a 3.5-month, double-blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing. At baseline, subjects underwent NAC with lavage for prostaglandin D2 measurement, skin prick test titration (SPTT), and blood sampling for basophil histamine release (BHR) and basophil IgE/Fcε{lunate}RI measurements. Basophil studies were repeated at day 3 and then weekly until cat allergen-induced BHR was 2) were only significantly reduced by the final NAC. Subjects on placebo (n = 4) did not experience a shift in basophil, NAC symptom, or mast cell measures. Conclusion: Reduction in nasal symptom scores occurred when the basophil, but not mast cell, response was reduced on omalizumab, implicating a role for basophils in the acute NAC response.

Original languageEnglish (US)
JournalThe Journal of Allergy and Clinical Immunology
Volume125
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Basophils
Mast Cells
Allergens
Cats
Nose
Histamine Release
Placebos
Omalizumab
Prostaglandin D2
Therapeutic Irrigation
Skin Tests
Immunoglobulin E
Hypersensitivity
Skin

Keywords

  • basophil histamine release
  • basophils
  • cat allergy
  • IgE
  • IgE receptors
  • mast cells
  • nasal allergen challenge
  • omalizumab
  • skin prick test titration

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. / Eckman, John A.; Sterba, Patricia M.; Kelly, Denise; Alexander, Val; Liu, Mark Chang Hwa; Bochner, Bruce S.; Macglashan, Donald; Saini, Sarbjit S.

In: The Journal of Allergy and Clinical Immunology, Vol. 125, No. 4, 04.2010.

Research output: Contribution to journalArticle

@article{1157443d75924bd88d7b8ffb355b1a6e,
title = "Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge",
abstract = "Background: Omalizumab treatment suppresses Fcε{lunate}RI expression faster on blood basophils than skin mast cells. Objective: We used omalizumab to elucidate the relative contributions of basophil versus mast cell Fcε{lunate}RI activation in a nasal allergen challenge (NAC) model. Methods: Eighteen subjects with cat allergy were enrolled in a 3.5-month, double-blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing. At baseline, subjects underwent NAC with lavage for prostaglandin D2 measurement, skin prick test titration (SPTT), and blood sampling for basophil histamine release (BHR) and basophil IgE/Fcε{lunate}RI measurements. Basophil studies were repeated at day 3 and then weekly until cat allergen-induced BHR was 2) were only significantly reduced by the final NAC. Subjects on placebo (n = 4) did not experience a shift in basophil, NAC symptom, or mast cell measures. Conclusion: Reduction in nasal symptom scores occurred when the basophil, but not mast cell, response was reduced on omalizumab, implicating a role for basophils in the acute NAC response.",
keywords = "basophil histamine release, basophils, cat allergy, IgE, IgE receptors, mast cells, nasal allergen challenge, omalizumab, skin prick test titration",
author = "Eckman, {John A.} and Sterba, {Patricia M.} and Denise Kelly and Val Alexander and Liu, {Mark Chang Hwa} and Bochner, {Bruce S.} and Donald Macglashan and Saini, {Sarbjit S}",
year = "2010",
month = "4",
doi = "10.1016/j.jaci.2009.09.012",
language = "English (US)",
volume = "125",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

AU - Eckman, John A.

AU - Sterba, Patricia M.

AU - Kelly, Denise

AU - Alexander, Val

AU - Liu, Mark Chang Hwa

AU - Bochner, Bruce S.

AU - Macglashan, Donald

AU - Saini, Sarbjit S

PY - 2010/4

Y1 - 2010/4

N2 - Background: Omalizumab treatment suppresses Fcε{lunate}RI expression faster on blood basophils than skin mast cells. Objective: We used omalizumab to elucidate the relative contributions of basophil versus mast cell Fcε{lunate}RI activation in a nasal allergen challenge (NAC) model. Methods: Eighteen subjects with cat allergy were enrolled in a 3.5-month, double-blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing. At baseline, subjects underwent NAC with lavage for prostaglandin D2 measurement, skin prick test titration (SPTT), and blood sampling for basophil histamine release (BHR) and basophil IgE/Fcε{lunate}RI measurements. Basophil studies were repeated at day 3 and then weekly until cat allergen-induced BHR was 2) were only significantly reduced by the final NAC. Subjects on placebo (n = 4) did not experience a shift in basophil, NAC symptom, or mast cell measures. Conclusion: Reduction in nasal symptom scores occurred when the basophil, but not mast cell, response was reduced on omalizumab, implicating a role for basophils in the acute NAC response.

AB - Background: Omalizumab treatment suppresses Fcε{lunate}RI expression faster on blood basophils than skin mast cells. Objective: We used omalizumab to elucidate the relative contributions of basophil versus mast cell Fcε{lunate}RI activation in a nasal allergen challenge (NAC) model. Methods: Eighteen subjects with cat allergy were enrolled in a 3.5-month, double-blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing. At baseline, subjects underwent NAC with lavage for prostaglandin D2 measurement, skin prick test titration (SPTT), and blood sampling for basophil histamine release (BHR) and basophil IgE/Fcε{lunate}RI measurements. Basophil studies were repeated at day 3 and then weekly until cat allergen-induced BHR was 2) were only significantly reduced by the final NAC. Subjects on placebo (n = 4) did not experience a shift in basophil, NAC symptom, or mast cell measures. Conclusion: Reduction in nasal symptom scores occurred when the basophil, but not mast cell, response was reduced on omalizumab, implicating a role for basophils in the acute NAC response.

KW - basophil histamine release

KW - basophils

KW - cat allergy

KW - IgE

KW - IgE receptors

KW - mast cells

KW - nasal allergen challenge

KW - omalizumab

KW - skin prick test titration

UR - http://www.scopus.com/inward/record.url?scp=77950296135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950296135&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2009.09.012

DO - 10.1016/j.jaci.2009.09.012

M3 - Article

VL - 125

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -